NCT04337177 2025-09-23
Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Phase 1 Recruiting
Valent Technologies, LLC
Second Life Therapeutics
Bayer
PersonGen BioTherapeutics (Suzhou) Co., Ltd.